Cure8 news brief
Perianal fistulas are a common and debilitating complication of Crohn’s disease that often need medical and surgical care. A Phase 3 trial reporting improved fistula remission with an IL-23–targeting therapy could offer an additional treatment option for adults with this specific, difficult-to-treat manifestation.
The subgroup analyses suggest the benefit was seen across patients with prior biologic exposure and differing disease features, which may be relevant for patients who have tried other advanced therapies.
Adults with Crohn’s disease and active perianal fistulas; patients who previously used biologics; gastroenterologists and IBD clinicians; researchers studying fistulizing Crohn’s disease or IL-23 therapies.
This press release summarizes prespecified subgroup analyses from the Phase 3 FUZION trial showing consistent combined fistula remission with TREMFYA versus placebo at Week 24 in adults with Crohn’s disease and MRI-confirmed draining perianal fistulas.
The company reports remission rates in the overall study and in subgroups (for example, patients with prior biologic exposure and with/without proctitis). Safety was reported as consistent with the known profile.
The FUZION study was a randomized, double-blind, placebo-controlled Phase 3 trial; the release includes the trial registration number and descriptions of eligibility and dosing arms. The article is a company press release from Johnson & Johnson/Cision PR Newswire and presents selected trial data being shown at ACG 2026.
The release highlights TREMFYA as the only IL-23 inhibitor with positive results in a dedicated randomized, placebo-controlled trial for Crohn’s disease with perianal fistula and notes some underlying mechanistic information about the drug drawn from in vitro studies.
This is a company press release summarizing prespecified Phase 3 subgroup analyses presented at a scientific meeting. While it cites the randomized, placebo-controlled FUZION trial and gives remission rates, press releases highlight selected results and may not include full data, independent peer review, or complete safety details.
The trial registration number (NCT05347095) is provided; consult the full study report, peer-reviewed publication, or independent guidelines for comprehensive interpretation.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Perianal fistulas are a common, hard-to-heal complication of Crohn's disease. This review collects current options beyond infliximab and explains where evidence is stronger or still emerging, which can help patients and...
Perianal fistulas are a significant complication of Crohn’s disease that can be hard to treat. A phase 3 trial reported that guselkumab improved combined fistula remission versus placebo, which could represent a new...
If approved, Tremfya SC induction could provide a fully subcutaneous induction and maintenance option for people with moderately to severely active ulcerative colitis, which may be more convenient than IV induction.
